{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Voxelotor&page=2", "query": { "intervention": "Voxelotor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Voxelotor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T17:09:52.822Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03943615", "title": "Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03943615" }, { "nct_id": "NCT03036813", "title": "Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "voxelotor", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 449, "start_date": "2016-12", "completion_date": "2019-10-08", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03036813" }, { "nct_id": "NCT04724421", "title": "Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Months to 11 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 33, "location_summary": "Phoenix, Arizona • San Diego, California • Wilmington, Delaware + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04724421" }, { "nct_id": "NCT04188509", "title": "Open-Label Extension of Voxelotor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 162, "start_date": "2019-11-18", "completion_date": "2024-11-01", "has_results": true, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04188509" }, { "nct_id": "NCT05228821", "title": "Voxelotor Brain Oxygenation and Neurocognitive Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Years to 30 Years" }, "enrollment_count": 0, "start_date": "2023-08-09", "completion_date": "2023-08-23", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 2, "location_summary": "St Louis, Missouri • The Bronx, New York", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05228821" }, { "nct_id": "NCT04581356", "title": "Voxelotor Sickle Cell Exercise Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sickle Cell Anemia" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elizabeth Yang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 14, "start_date": "2020-09-21", "completion_date": "2021-12-29", "has_results": false, "last_update_posted_date": "2022-06-15", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04581356" }, { "nct_id": "NCT05981365", "title": "Voxelotor CYP and Transporter Cocktail Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Flurbiprofen", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2023-04-17", "completion_date": "2023-10-04", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05981365" }, { "nct_id": "NCT02567682", "title": "Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "GBT440", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Blood Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2015-09", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02567682" }, { "nct_id": "NCT03161015", "title": "Single-Dose PK Study of GBT440 in Subjects With Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment" ], "interventions": [ { "name": "GBT440", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Blood Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2016-11", "completion_date": "2017-07-06", "has_results": false, "last_update_posted_date": "2018-02-22", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 2, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03161015" }, { "nct_id": "NCT02989168", "title": "Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis", "Hypoxemia" ], "interventions": [ { "name": "GBT440", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Blood Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "45 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2016-11", "completion_date": "2017-10-23", "has_results": true, "last_update_posted_date": "2020-08-21", "last_synced_at": "2026-09-27T17:09:52.822Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Denver, Colorado • New Orleans, Louisiana + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02989168" } ] }